Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients

Inclusion Criteria: * Patients HIV positive \> 18 years. * Patients in treatment with Sustiva(r)+Truvada(r); or Sustiva (r)+Kivexa(r). * HIV-ARN \< 50 copies/mL in the las six months. * Clinically evident lipoatrophy (moderate or severe). * Negative pregnancy test. * Signed informed consent. Exclusion Criteria: * Evidence of failure or mutation to therapy with protease inhibitors. * Patients that can not be treated with LPV/r. * Mild lipoatrophy. * History of alcoholism or drug addiction that discourages participation in the study. * Pregnancy or breastfeeding. * Documented current or 4 weeks prior opportunistic infection. * Creatinin clearance \< 60mL/min. * Concomitant use of nephrotoxic drugs or immunosuppressants. * Actual treatment with systemic corticosteroids, IL-2 or chemotherapy. * Patients under treatment with other drugs in investigation. * Acute hepatitis. * Any other disease that discourages participation.